{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T02:32:05Z","timestamp":1768098725192,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,8]]},"DOI":"10.1093\/ibd\/izy044","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T05:34:04Z","timestamp":1523597644000},"page":"1531-1538","source":"Crossref","is-referenced-by-count":37,"title":["Therapeutic Drug Monitoring Guides the Management of Crohn\u2019s Patients with Secondary Loss of Response to Adalimumab"],"prefix":"10.1093","volume":"24","author":[{"given":"Sophie","family":"Restellini","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre, Montreal, Canada"},{"name":"Division of Gastroenterology and Hepatology, Geneva\u2019s University Hospitals and University of Geneva, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-yung","family":"Chao","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre, Montreal, Canada"},{"name":"Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre, Montreal, Canada"},{"name":"1st Department of Medicine, Semmelweis University, Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achuthan","family":"Aruljothy","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, McGill University Health Centre, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haya","family":"Aziz","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, McGill University Health Centre, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Kherad","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, La Tour Hospital and University of Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Wild","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Centre, Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"key\n\t\t\t\t20180608110741_CIT0001","first-page":"28","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180608110741_CIT0002","first-page":"991","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180608110741_CIT0003","first-page":"323","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180608110741_CIT0004","first-page":"429","article-title":"Optimization of anti-TNF therapy in patients with inflammatory bowel disease","volume":"9","author":"Strik","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key\n\t\t\t\t20180608110741_CIT0005","first-page":"80","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180608110741_CIT0006","first-page":"100","article-title":"Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u2019s disease","volume":"49","author":"Imaeda","year":"2014","journal-title":"J Gastroenterol"},{"key":"key\n\t\t\t\t20180608110741_CIT0007","first-page":"620","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180608110741_CIT0008","first-page":"1112","article-title":"Serum adalimumab concentration and clinical remission in patients with Crohn\u2019s disease","volume":"19","author":"Chiu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180608110741_CIT0009","first-page":"150","article-title":"Infliximab and adalimumab drug levels in Crohn\u2019s disease: contrasting associations with disease activity and influencing factors","volume":"46","author":"Ward","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180608110741_CIT0010","first-page":"550","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180608110741_CIT0011","first-page":"510","article-title":"Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn\u2019s disease","volume":"10","author":"Zittan","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180608110741_CIT0012","first-page":"535","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J Gastroenterol"},{"key":"key\n\t\t\t\t20180608110741_CIT0013","first-page":"522","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180608110741_CIT0014","first-page":"154","article-title":"Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn\u2019s patients","volume":"7","author":"Baert","year":"2013","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180608110741_CIT0015","first-page":"1044","article-title":"Adalimumab dose escalation is effective for managing secondary loss of response in Crohn\u2019s disease","volume":"40","author":"Ma","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180608110741_CIT0016","first-page":"S222-S","article-title":"P283 Quantum blue\u00ae adalimumab: development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levels","volume":"11","author":"Bantleon","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180608110741_CIT0017","first-page":"1628","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180608110741_CIT0018","first-page":"1288","article-title":"Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"20","author":"Paul","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180608110741_CIT0019","first-page":"1079","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/7\/1531\/25026693\/izy044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T15:08:10Z","timestamp":1528470490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/7\/1531\/4969821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,4,13]]},"published-print":{"date-parts":[[2018,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy044","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7]]},"published":{"date-parts":[[2018,4,13]]}}}